We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

By LabMedica International staff writers
Posted on 06 Oct 2021
Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. More...
One of the cornerstones of immunology has been the detailed phenotypic classification of the cellular populations of the immune system.

Modern flow cytometric approaches exemplify this by using panels of multiple fluorochrome-conjugated (conventional flow cytometry) or metal-conjugated (mass cytometry) antibodies to measure protein expression profiles of individual cells with high cell throughput to capture and analyze both common and rare cell populations.

Clinical Scientists at the Fred Hutchinson Cancer Institute (Seattle, WA, USA) developed a workflow that enables highly multiplexed analysis of cell surface proteins using conventional flow cytometry. The method uses machine learning combined with data from overlapping flow cytometry assay panels to determine the co-expression patterns of hundreds of cell surface markers across millions of single cells.

The approach, named Infinity Flow, uses traditional flow cytometry as opposed to newer technologies like mass cytometry; it offers a potentially more accessible and less expensive route for single-cell proteomic studies. The method consists of two steps. First, the scientists stain all the cells in an experiment with antibodies to a small number of proteins. This is called the "backbone" panel and typically consists of around the 20 analytes that can be multiplexed using a conventional flow cytometer.

The scientists then subdivide the sample into a series of wells, each containing one of the additional antibodies to the proteins they are interested in. For instance, if the investigator want to look at another 200 proteins beyond those covered in the backbone panel, they would subdivide their sample into 200 different wells, each of which would contain an antibody against one of those 200 proteins. They then analyze each well of samples using flow cytometry, the BD Fortessa X-20 cytometer (BD Biosciences, Franklin Lakes, NJ, USA) allowing them to collect for each cell expression data on all of the "backbone" proteins along with data on the one additional protein designated for that sample well. With this data, the Infinity Flow software is able to predict for every cell being analyzed the expression levels of the 200 proteins of interest.

The team found that when they used a backbone panel of proteins common to all T cells, they were unable to impute protein expression levels for particular T-cell types due to the fact that, based on the backbone signature, all T cells looked the same. This, they noted, indicates that tailoring backbone panels to the samples and cell populations of interest can improve the assay's performance. They also found that the method was best able to impute expression levels for proteins that exhibited multimodal expression patterns and were highly or commonly expressed. In an evaluation of an Infinity Flow assay detailed in the study, they determined that they were able to generate "meaningful imputed signal" for 155 of 252 markers measured.

Mark Headley, PhD, an assistant professor in immunology and a leading author of the study, said, “Infinity Flow costs scale more slowly. We can measure 10 million, 20 million, 30 million cells at the same cost. It doesn't cost you more to do the assay the more cells you do.” The study was published on September 22, 2021 in the journal Science Advances.

Related Links:
Fred Hutchinson Cancer Institute
BD Biosciences




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.